BPG is committed to discovery and dissemination of knowledge
Case Report
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 6, 2023; 11(28): 6889-6894
Published online Oct 6, 2023. doi: 10.12998/wjcc.v11.i28.6889
Primary cutaneous anaplastic large cell lymphoma with over-expressed Ki-67 transitioning into systemic anaplastic large cell lymphoma: A case report
Hai-Xi Mu, Xiao-Qiong Tang
Hai-Xi Mu, Xiao-Qiong Tang, Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
Author contributions: Mu HX contributed to manuscript writing and editing and data collection; Tang XQ contributed to conceptualization and supervision; all authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Xiao-Qiong Tang, MD, Chief Physician, Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong, Chongqing 400010, China. tangxiaoqiong@126.com
Received: June 19, 2023
Peer-review started: June 19, 2023
First decision: August 16, 2023
Revised: August 30, 2023
Accepted: September 6, 2023
Article in press: September 6, 2023
Published online: October 6, 2023
Processing time: 98 Days and 5.5 Hours
Core Tip

Core Tip: Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a primary cutaneous lymphoma and differs from systemic anaplastic large cell lymphoma (sALCL), which is a peripheral T cell lymphoma. There is no direct connection between them. This is the first report of the medical management, including auto-hematopoietic stem cell transplantation (ASCT) of a 43-year-old male patient who transitioned from the cutaneous to the systemic form of ALCL in Asia, and the second to be reported in world (the first being a Bulgarian treated with Brentuximab vedontin). We found high expression of Ki-67 in this case, for the first time, which may have played a role in the transition. This is also the first instance of application of auto-ASCT followed by maintenance with oral chidamide. In the future, an increasing number of patients will probably receive this therapy, and therein lies the significance of this case report.

Write to the Help Desk